Previous studies have shown that trastuzumab treatment in combination with DCs pulsed with HER2 peptides E75 or GP2 and GM-CSF were able to generate CD8+ T cell immune response in HER2+ BC patients and enhanced DC-mediated presentation of E75 peptides in preclinical model of HER2+ BC (158, 159, 165). The gene discussed is CD8A; the disease is breast cancer.